Loading...
•
Dec 31, 2025
Quanterix Q4 2025 Earnings Report
Quanterix Q4 2025 Earnings Report
Key Takeaways
Quanterix reported strong Q4 2025 revenue growth of 25% year-over-year, reaching $43.9 million, driven by product sales. Despite a decline in gross margins due to acquisition-related impacts, the company is progressing toward its goal of cash flow breakeven in 2026 following the integration of Akoya Biosciences.
Q4 revenue grew 25% year-over-year to $43.9 million, exceeding internal expectations.
Submitted 510(k) premarket notification to the FDA for a multi-analyte Alzheimer’s blood test in January 2026.
Achieved $74 million in cost savings related to the Akoya transaction with 94% of integration milestones complete.
CMS established a reimbursement rate of $897 for the LucentAD Complete test, a key milestone for diagnostic commercialization.
Revenue by Segment
Forward Guidance
Quanterix expects significant revenue growth in 2026 and aims to reach cash flow breakeven in the second half of the year.
Positive Outlook
- Full year 2026 revenue guidance of $169 million to $174 million.
- Expected adjusted gross margin improvement to 49-53%.
- Targeting cash flow breakeven performance in H2 2026.
- Expects to exit 2026 with approximately $100 million in cash and no debt.
- Remaining Akoya cost synergies expected to be captured by end of Q1 2026.
Challenges Ahead
- GAAP gross margin guidance (45-49%) remains lower than historical 2024 levels.
- Integration of Akoya could be more difficult or costly than expected.
- Risks related to federal research funding reductions.
- Potential for defects or quality issues in next-generation instruments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...